Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Clinical High Risk for Psychosis
NCT07434973Phase 3Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Clinical high risk for psychosis (CHR) (3 arms), sponsored by University of Oxford. Primary endpoint: Change from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score) at 104 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Clinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on NCT07434973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434973.